Royalty Pharma appoints Vlad Coric, M.D., to Board of Directors effective April 7, 2025.

Royalty Pharma plc

Dr. Vlad Coric appointed to Royalty Pharma Board effective April 7, 2025.
He is Chairman and CEO of Biohaven, led Nurtec ODT approval and $13B sale to Pfizer.
Coric will stand for election at 2025 Annual Meeting; if elected, expected to join Compensation Committee.
Board determined Coric meets Nasdaq independence standards; will receive standard independent director compensation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vlad Coric

Director

RPRX · Royalty Pharma plc

Effective: 2025-04-07
Filed: April 10, 2025, 7:59 PM ET

Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vlad Coric was appointed as Director at Royalty Pharma plc.

Action: appointed
Role: Director

Exact text from the filing

Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).

View on SEC.gov

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001193125-25-077950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.